Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

HER2-positive Breast Cancer × trastuzumab deruxtecan × 1 year × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 51 Neoplasm Metastasis 20 Carcinoma, Non-Small-Cell Lung 10 Stomach Neoplasms 8 Brain Neoplasms 8 Colorectal Neoplasms 5 Triple Negative Breast Neoplasms 4 Ovarian Neoplasms 4 Endometrial Neoplasms 4 Salivary Gland Neoplasms 3 Recurrence 3 Pancreatic Neoplasms 3 Neoplasms 3 Adenocarcinoma 3 Prostatic Neoplasms 2 Meningeal Carcinomatosis 2 HER2-positive Gastric Cancer 2 Esophageal Neoplasms 2 Breast Cancer With Brain Metastasis 2 Advanced Breast Cancer 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Thyroid Neoplasms 1 Testicular Neoplasms 1 Solid Cancer 1 Small Cell Lung Carcinoma 1

Interventions

Trastuzumab 13 pertuzumab 8 Docetaxel 6 tucatinib 5 pyrotinib 4 Capecitabine 4 Paclitaxel 3 Carboplatin 2 Ado-Trastuzumab Emtansine 2 trastuzumab deruxtecan 1 pegfilgrastim 1 neratinib 1 exemestane 1 dalpiciclib 1 Leuprolide 1 Isovaleryl-CoA Dehydrogenase 1 Injections 1 Goserelin 1 Fulvestrant 1 Fluorodeoxyglucose F18 1 Anastrozole 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05982678 2025-11-26

ANISE

The Netherlands Cancer Institute

Phase 2 Recruiting

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡